Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

112.20 -1.07 (-0.94%)

Delayed Quote Updated: 1:25 PM EDT, Oct 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

29 30 Next >

7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff ↗

February 26, 2024

Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.

Via InvestorPlace

NASDAQ:INCY stands out as a growth opportunity that won't break the bank. ↗

February 22, 2024

For those who appreciate growth without the sticker shock, INCYTE CORP (NASDAQ:INCY) is worth considering.

Via Chartmill

Exit Now! 3 Biotech Stocks to Sell in February 2024 ↗

February 21, 2024

These biotech stocks to sell represent incredibly risky bets, amidst the sector's volatility and looming economic unpredictability.

Via InvestorPlace

Incyte to Present at Upcoming Investor Conference

February 15, 2024

From Incyte

Via Business Wire

The Analyst Verdict: Incyte In The Eyes Of 8 Experts ↗

February 14, 2024

Via Benzinga

NASDAQ:INCY is not too expensive for the growth it is showing. ↗

February 01, 2024

INCYTE CORP (NASDAQ:INCY) is not too expensive for the growth it is showing.

Via Chartmill

Expert Ratings for Incyte ↗

December 13, 2023

Via Benzinga

What's Up With Incyte Stock Lately? ↗

December 12, 2023

Incyte Corporation (NASDAQ: INCY) shares are trading higher on Tuesday. The stock has risen rapidly since Monday.

Via Benzinga

Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities

February 13, 2024

From Incyte

Via Business Wire

Despite its impressive fundamentals, NASDAQ:INCY remains undervalued. ↗

February 12, 2024

INCYTE CORP (NASDAQ:INCY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

Pancreatic Cancer Treatments Poised for Major Advances in 2024

February 07, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B ↗

February 06, 2024

Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tulmimetostat.

Via Benzinga

Earnings Scheduled For February 13, 2024 ↗

February 13, 2024

Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million.

Via Benzinga

Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion ↗

February 05, 2024

Novartis will add to its cancer treatment pipeline with via the German biotech.

Via Investor's Business Daily

Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)

February 05, 2024

From Incyte

Via Business Wire

Why Is MorphoSys (MOR) Stock Up 50% Today? ↗

February 05, 2024

News of a potential takeout bid for any company usually leads to a big surge. That's what investors are seeing today with MOR stock.

Via InvestorPlace

MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer ↗

February 05, 2024

Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold...

Via Benzinga

5 top healthcare stocks for earnings growth in 2024

January 25, 2024

2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed.

Via MarketBeat

Incyte to Report Fourth Quarter and Year-End 2023 Financial Results

January 23, 2024

From Incyte

Via Business Wire

NASDAQ:INCY is probably undervalued for the fundamentals it is displaying. ↗

January 19, 2024

For those who appreciate value investing, INCYTE CORP (NASDAQ:INCY) is a compelling option with its solid fundamentals.

Via Chartmill

3 Pharma Stocks Could Be the Pills Your Portfolio Needs ↗

January 18, 2024

These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations.

Via InvestorPlace

Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations ↗

January 10, 2024

Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to

Via Benzinga

In the world of growth stocks, NASDAQ:INCY shines as a value proposition. ↗

January 10, 2024

Investors seeking growth at a reasonable cost should explore INCYTE CORP (NASDAQ:INCY).

Via Chartmill

Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference

January 08, 2024

From Incyte

Via Business Wire

For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals. ↗

December 28, 2023

In a market where value is scarce, INCYTE CORP (NASDAQ:INCY) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

NASDAQ:INCY is showing decent growth, but is still valued reasonably. ↗

December 19, 2023

For those who appreciate growth without the sticker shock, INCYTE CORP (NASDAQ:INCY) is worth considering.

Via Chartmill

AI Meets Biotech: 3 Top Stocks Transforming Medical Science ↗

December 16, 2023

The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.

Via InvestorPlace

Topics Artificial Intelligence

The 3 Most Undervalued Biotech Stocks to Buy in December ↗

December 15, 2023

Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks.

Via InvestorPlace

Incyte to Present at Upcoming Investor Conferences

December 12, 2023

From Incyte

Via Business Wire

Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

December 10, 2023

From Incyte and Syndax Pharmaceuticals

Via Business Wire

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.